Biohaven Ltd.

Biohaven Pharmaceutical Holding Company Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and psychiatric disorders, particularly in migraine treatment and other related conditions. Founded in 2014 in New Haven, US, Biohaven Pharmaceutical Holding Company Ltd. is dedicated to advancing biopharmaceutical solutions.

The company has raised a total of USD 125. 00 mn through funding, including a Private Placement/Follow on round in December 2018 that garnered USD 125. 00 mn. The company has completed 7 deals to date.

Biohaven was founded by Rob Berman, who has a history in the pharmaceutical industry. Biohaven is engaged in discovering and developing treatment solutions primarily in neuroscience, immunology, and oncology. Its main products include Nurtec® ODT (rimegepant) and Zavzpret® (zavegepant), both targeting acute migraine treatment. Nurtec® ODT was approved by the FDA in February 2020 and functions as a CGRP receptor antagonist.

The company also has a pipeline featuring candidates like BHV-1300 and BHV-1400, aimed at conditions such as IgA nephropathy and neuroinflammation in early Parkinson's disease. Products are marketed mainly in the US and select international markets through healthcare providers, hospitals, and specialty pharmacies. In the most recent year, 2021, Biohaven reported a revenue of USD 462. 51 mn with an EBITDA of USD -679.

11 mn. The revenue is primarily generated from prescriptions of Nurtec® ODT and Zavzpret®, with a sales model that relies on healthcare professionals prescribing these medications, which are then dispensed through retail or specialty pharmacies. The pricing is reflective of the advanced solutions provided to address unmet medical needs, supported by ongoing clinical trials and anticipated new product launches. Biohaven plans to expand its product offerings and market reach.

The company is developing new products aimed at enhancing treatment options for neurological conditions, with an emphasis on launching additional therapies in the next few years. Biohaven intends to leverage the recent funding from its December 2018 round, where it raised USD 125. 00 mn, to support these new product initiatives and enter new markets. Expansion is targeted towards broader geographic areas, including Europe and Asia, to increase access to its therapies.

In April 2025, Oberland Capital Management agreed to acquire approximately USD 600 million in senior secured notes from Biohaven Pharmaceutical Holding Company Ltd. The financing includes a first tranche, totaling USD 250 million funded by April 30, 2025. A second tranche of a USD 150 million will become available if troriluzole receives approval from the U. S.

Food and Drug Administration (FDA) and other conditions are met. Additionally, up to USD 200 million may be provided for strategic acquisitions and related expenses, pending mutual agreement between the parties.